公开(公告)号：WO2007095602A2

公开(公告)日：2007-08-23

申请号：PCT/US2007/062180

申请日：2007-02-15

Applicant: ABBOTT LABORATORIES ,  GU, Yu Gui ,  WEITZBERG, Moshe ,  XU, Xiangdong ,  CLARK, Richard, F. ,  ZHANG, Tianyuan ,  LI, Qun ,  HANSEN, Todd, M. ,  SHAM, Hing ,  BEUTEL, Bruce, A. ,  CAMP, Heidi, S. ,  WANG, Xiaojun

Inventor： GU, Yu Gui ,  WEITZBERG, Moshe ,  XU, Xiangdong ,  CLARK, Richard, F. ,  ZHANG, Tianyuan ,  LI, Qun ,  HANSEN, Todd, M. ,  SHAM, Hing ,  BEUTEL, Bruce, A. ,  CAMP, Heidi, S. ,  WANG, Xiaojun

CPC classification number: C07D277/34 ,  C07D261/08 ,  C07D277/56 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: The present invention relates to compounds of Formula (I), which inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of metabolic syndrome, type II diabetes, obesity, atherosclerosis and cardiovascular diseases in humans.

Abstract translation: 本发明涉及抑制乙酰辅酶A羧化酶（ACC）并可用于预防或治疗代谢综合征，II型糖尿病，肥胖症，动脉粥样硬化和心血管疾病的式（I）化合物 人类疾病。

公开(公告)号：WO2004083207A1

公开(公告)日：2004-09-30

申请号：PCT/US2003/007689

申请日：2003-03-12

Applicant: ABBOTT LABORATORIES

Inventor： ANDERSON, David ,  BEUTEL, Bruce ,  BOSSE, Todd, D. ,  CLARK, Richard ,  COOPER, Curt ,  DANDLIKER, Peter ,  DAVID, Caroline ,  GU, Yu-Gui ,  HANSEN, Todd, Matthew ,  HINMAN, Mira ,  KALVIN, Douglas ,  LARSON, Daniel, P. ,  LYNCH, Linda ,  MA, Zhenkun ,  MOTTER, Christopher ,  PALAZZO, Fabio ,  ROSENBERG, Teresa ,  REHM, Tamara ,  SANDERS, William ,  TUFANO, Michael ,  WAGNER, Rolf ,  WEITZBERG, Moshe ,  YONG, Hong ,  ZHANG, Tianyuan

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Antibacterials having formula (I), and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the processes, compositions containing the compounds, and methods of prophylaxis and treatment of bacterial infections using the compounds are disclosed.

Abstract translation: 公开了具有式（I）的抗菌剂及其前体药物的盐，前药和盐，用于制备本方法中使用的化合物和中间体的方法，含该化合物的组合物，以及使用该化合物预防和治疗细菌感染的方法。

公开(公告)号：EP1631570A1

公开(公告)日：2006-03-08

申请号：EP03723732.8

申请日：2003-03-12

Applicant: ABBOTT LABORATORIES

Inventor： ANDERSON, David ,  BEUTEL, Bruce ,  BOSSE, Todd, D. ,  CLARK, Richard ,  COOPER, Curt ,  DANDLIKER, Peter ,  DAVID, Caroline ,  GU, Yu-Gui ,  HANSEN, Todd, Matthew ,  HINMAN, Mira ,  KALVIN, Douglas ,  LARSON, Daniel, P. ,  LYNCH, Linda ,  MA, Zhenkun ,  MOTTER, Christopher ,  PALAZZO, Fabio ,  ROSENBERG, Teresa ,  REHM, Tamara ,  SANDERS, William ,  TUFANO, Michael ,  WAGNER, Rolf ,  WEITZBERG, Moshe ,  YONG, Hong ,  ZHANG, Tianyuan

IPC: C07D471/04 ,  A61K31/435 ,  A61P31/04

CPC classification number: C07D471/04

Abstract: Antibacterials having formula (I), and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the processes, compositions containing the compounds, and methods of prophylaxis and treatment of bacterial infections using the compounds are disclosed.

公开(公告)号：EP1999119A2

公开(公告)日：2008-12-10

申请号：EP07757026.5

申请日：2007-02-15

Applicant: ABBOTT LABORATORIES

Inventor： GU, Yu Gui ,  WEITZBERG, Moshe ,  XU, Xiangdong ,  CLARK, Richard, F. ,  ZHANG, Tianyuan ,  LI, Qun ,  HANSEN, Todd, M. ,  SHAM, Hing ,  BEUTEL, Bruce, A. ,  CAMP, Heidi, S. ,  WANG, Xiaojun

IPC: C07D277/34 ,  A61K31/427 ,  C07D261/08 ,  C07D277/56 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

CPC classification number: C07D277/34 ,  C07D261/08 ,  C07D277/56 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: The present invention relates to compounds of formula (I), wherein R1 is selected from the group consisting of hydrogen, cycloalkyl, alkyl and haloalkyl; Y is selected from the group consisting of -(CR4aR-4b)m-, -C(O)-, -O-, -N(H)-, -N(alkyl)- and -S-; wherein m is 1, 2 or 3; Ar3 is phenyl or monocyclic heteroaryl; wherein Ar3 is substituted with 1, 2 or 3 or 4 substituents. Ar1 is selected from the group consisting of phenyl and a monocyclic, five or six- membered heteroaryl; Ar2 is a monocyclic five membered heteroaryl, wherein each Ar2 is independently unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of alkyl, alkenyl, halogen, -CN, -NO2, hydroxy, alkoxy, -NH2, -N(H)(alkyl), -N(alkyl)2. -C(O)OH, -C(O)Oalkyl, -C(O)H, -C(O)alkyl, and haloalkyl; Z is selected from the group consisting of -OR9a, -alkylenyl-OR9a, -NR6R99b; and -alkylenyl-NR6R9b; which inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of metabolic syndrome, type U diabetes, obesity, atherosclerosis and cardiovascular diseases in humans.